What effects does Tucatinib have? Is it widely applicable?

Tucatinib (trade name: Tukysa, Chinese translation: tucatinib) is a selective HER2 inhibitor, mainly used to treat HER2 positive breast cancer, especially in advanced or metastatic patients with significant efficacy. It inhibits the growth and spread of cancer cells by highly selectively inhibiting HER2 tyrosine kinase activity, thereby blocking the HER2 signaling pathway. Unlike other pan-HER inhibitors, tucatinib has a weaker inhibitory effect on EGFR, resulting in fewer side effects and better tolerability.

The therapeutic effect of tucatinib has been verified in multiple international clinical studies. Especially in the HER2CLIMB study, tucatinib combined with trastuzumab and capecitabine significantly improved the progression-free survival and overall survival of patients, and also showed good efficacy in patients with brain metastases. This discovery makes tucatinib one of the few oral targeted drugs that can combat brain metastasis of HER2 positive breast cancer, bringing new treatment hope to this type of refractory patients.

Although tucatinib is currently mainly used to treat breast cancer, its HER2 targeting mechanism has also led researchers to focus on its potential in other HER2 expressing tumors. For example, some gastric cancers, lung cancers, colorectal cancers, etc. may also express HER2. Preliminary studies show that tucatinib also has certain activity in these tumors, and the scope of indications may be expanded in the future. However, the current application in these cancer types is still in the exploratory stage and has not yet been widely incorporated into standard treatment guidelines.

In general, tucatinib is an antiHER2 targeted drug with a clear target, definite efficacy, and relatively controllable side effects. It has gained international recognition in the treatment of HER2positive advanced breast cancer and is expected to be expanded to more HER2 related tumor types in the future. However, in clinical use, individualized plans still need to be formulated based on the patient's specific situation, HER2 expression level and previous treatment history.

Reference materials:https://www.drugs.com/